166411-43-4

Basic information

• Product Name: 5-O-benzoyl-3-deoxy-1,2-O-isopropylidene-α-L-erythro-pentofuranose
• Synonyms: 5-O-benzoyl-3-deoxy-1,2-O-isopropylidene-α-L-erythro-pentofuranose
• CAS NO: 166411-43-4
• Molecular Weight: 278.305
• Mol File: 166411-43-4.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 5-O-benzoyl-3-deoxy-1,2-O-isopropylidene-α-L-erythro-pentofuranose(CAS DataBase Reference)
• NIST Chemistry Reference: 5-O-benzoyl-3-deoxy-1,2-O-isopropylidene-α-L-erythro-pentofuranose(166411-43-4)
• EPA Substance Registry System: 5-O-benzoyl-3-deoxy-1,2-O-isopropylidene-α-L-erythro-pentofuranose(166411-43-4)

Safety Data

• Hazardous Substances Data: 166411-43-4(Hazardous Substances Data)

Upstream product

• 100-44-7 benzyl chloride 
• 166411-40-1 5-O-benzoyl-1,2-O-isopropylidene-α-L-erythro-pentofuranose-3-ulose 
• 166411-41-2 5-O-benzoyl-1,2-O-isopropylidene-p-toluenesulfonylhydrazone-α-L-erythro-pentofurano-3-ulose 
• 98-88-4 benzoyl chloride 
• 114861-22-2 1,2-O-isopropylidene-α-L-xylofuranose 
• 41546-31-0 L-xylose 
• 511272-12-1 Benzoic acid (3aS,5S,6R,6aS)-2,2-dimethyl-6-methylsulfanylthiocarboxyoxy-tetrahydro-furo[2,3-d][1,3]dioxol-5-ylmethyl ester 
• 166411-39-8 5-O-benzoyl-1,2-O-isopropylidene-7α-L-xylofuranose 
• 169823-49-8 5-O-benzoyl-3-O-(imidazolylthiocarbonyl)-1,2-O-isopropylidene-α-L-xylofuranose 

Downstream Products

• 263708-28-7 methyl 1-(2-O-acetyl-5-O-benzoyl-3-deoxy-β-L-ribofuranosyl)-1,2,4-triazole-3-carboxylate 
• 169823-50-1 Benzoic acid (2R,4S,5S)-4-acetoxy-5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-2-ylmethyl ester 
• 170079-20-6 1,2-di-O-acetyl-5-O-benzoyl-3-deoxy-L-erythro-pentofuranose 
• 255818-76-9 2-isobutyrylamino-6-chloro-9-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)purine 
• 255818-77-0 2-isobutyrylamino-6-chloro-9-(5-O-benzoyl-2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)purine 
• 255818-50-9 5-iodo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil 
• 255818-51-0 5-iodo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)uracil 
• 255818-56-5 5-iodo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine 
• 186648-63-5 5-fluoro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil 
• 255818-47-4 5-fluoro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)uracil 
• 255818-48-5 5-bromo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)uracil 
• 255818-49-6 5-bromo-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-α-L-threo-pentofuranosyl)uracil 
• 255818-54-3 5-fluoro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine 
• 255818-58-7 5-chloro-1-(5-O-benzoyl-2,3-dideoxy-2-fluoro-β-L-threo-pentofuranosyl)cytosine 

Relevant articles and documents

Synthesis and antiviral evaluation of 3'-deoxy-β-L-erythro- pentofuranosyl nucleosides of the five naturally occurring nucleic acid bases

The hitherto unknown title compounds were stereospecifically synthesized by glycosylation of pyrimidine and purine aglycons with a suitably peracylated 3'-deoxy-β-L-erythro-pentofuranose, followed by removal of the protecting groups. All the prepared comp

Enantioselective total syntheses of slagenins A-C and their antipodes

Full details of the total syntheses of slagenins A-C (1a-c) and their antipodes (2a-c), novel bromopyrrole alkaloids with a unique tetrahydrofuro[2,3-d]imidazolidin-2-one moiety, are described in which their absolute stereochemistry was established. The key step in the syntheses involves the efficient condensation of dihydrofuran-3-one or glyoxal with urea to construct the slagenin bicycle core.

Monocyclic L-nucleosides with type 1 cytokine-inducing activity

A series of 1,2,4-triazole L-nucleosides were synthesized and evaluated for their ability to stimulate type i cytokine production by activated human T cells in direct comparison to the known active agent ribavirin. Among the compounds prepared, 1-β-L-ribofuranosyl-1,2,4-triazole-3-carboxamide (5, ICN 17261) was found to be the most uniformly potent compound. Conversion of the 3-carboxamide group of 5 to a carboxamidine functionality resulted in 1-β-L- ribofuranosyl-1,2,4-triazole-3-carboxamidine hydrochloride (10), which induced cytokine levels comparable to 5 for two of the three type 1 cytokines examined. Modification of the carbohydrate moiety of 5 provided compounds of reduced activity. Significantly, ICN 17261 offers interesting immunomodulatory potential for the treatment of diseases where type I cytokines play an important role.